Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BDTX Black Diamond Therapeutics	$2.33	$1.96	$1.20 ▼ $6.75	$132.49M	2.71	1.54 million shs	786,157 shs
LXEO Lexeo Therapeutics	$3.91 -7.8%	$3.36	$1.45 ▼ $19.50	$140.76M	0.52	530,698 shs	756,031 shs
PVCT Provectus Biopharmaceuticals	$0.07	$0.09	$0.04 ▼ $0.16	$31.48M	0.78	157,406 shs	216,380 shs
RAPT Rapt Therapeutics	$7.43 +0.1%	$7.46	$5.67 ▼ $30.60	$122.70M	-0.11	161,581 shs	152,905 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BDTX Black Diamond Therapeutics	0.00%	+0.87%	+14.78%	+30.90%	-56.20%
LXEO Lexeo Therapeutics	-7.78%	-0.76%	+27.78%	+44.28%	-75.00%
PVCT Provectus Biopharmaceuticals	0.00%	+1.63%	-6.49%	-29.41%	-52.59%
RAPT Rapt Therapeutics	+0.13%	-10.70%	+4.59%	-29.10%	-70.89%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BDTX Black Diamond Therapeutics	3.0859 of 5 stars	3.5	4.0	0.0	0.0	3.0	1.7	0.6
LXEO Lexeo Therapeutics	3.175 of 5 stars	4.5	2.0	0.0	0.0	1.4	2.5	0.6
PVCT Provectus Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RAPT Rapt Therapeutics	3.8985 of 5 stars	3.2	1.0	0.0	4.2	2.5	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BDTX Black Diamond Therapeutics	3.00	Buy	$14.60	526.61% Upside
LXEO Lexeo Therapeutics	3.00	Buy	$16.60	324.55% Upside
PVCT Provectus Biopharmaceuticals	0.00	N/A	N/A	N/A
RAPT Rapt Therapeutics	2.33	Hold	$24.00	223.01% Upside

Current Analyst Ratings Breakdown

Latest PVCT, BDTX, LXEO, and RAPT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/30/2025	LXEO Lexeo Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$16.00 ➝ $10.00
5/22/2025	RAPT Rapt Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$16.00 ➝ $8.00
5/22/2025	RAPT Rapt Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$48.00
5/16/2025	LXEO Lexeo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$23.00 ➝ $15.00
5/13/2025	LXEO Lexeo Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $20.00
4/8/2025	LXEO Lexeo Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$25.00 ➝ $22.00
4/8/2025	LXEO Lexeo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00
3/26/2025	LXEO Lexeo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00
3/25/2025	LXEO Lexeo Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$24.00 ➝ $20.00
3/25/2025	LXEO Lexeo Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00
3/24/2025	LXEO Lexeo Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$19.00 ➝ $18.00

(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BDTX Black Diamond Therapeutics	N/A	N/A	N/A	N/A	$1.47 per share	N/A
LXEO Lexeo Therapeutics	$650K	199.71	N/A	N/A	$3.53 per share	1.11
PVCT Provectus Biopharmaceuticals	$620K	50.77	N/A	N/A	($0.01) per share	-7.49
RAPT Rapt Therapeutics	$1.53M	80.32	N/A	N/A	$11.51 per share	0.65

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BDTX Black Diamond Therapeutics	-$69.68M	$0.06	38.83	N/A	N/A	N/A	4.70%	3.47%	8/5/2025 (Estimated)
LXEO Lexeo Therapeutics	-$98.33M	-$3.30	N/A	N/A	N/A	N/A	-85.86%	-68.48%	8/11/2025 (Estimated)
PVCT Provectus Biopharmaceuticals	-$4.76M	N/A	0.00	∞	N/A	-815.81%	N/A	-644.80%	8/11/2025 (Estimated)
RAPT Rapt Therapeutics	-$129.87M	-$2.40	N/A	N/A	N/A	N/A	-81.47%	-70.24%	8/6/2025 (Estimated)

Latest PVCT, BDTX, LXEO, and RAPT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	LXEO Lexeo Therapeutics	-$0.80	-$0.99	-$0.19	-$0.99	N/A	N/A
5/8/2025	Q1 2025	RAPT Rapt Therapeutics	-$2.48	-$0.64	+$1.84	-$0.08	N/A	N/A
3/24/2025	Q4 2024	LXEO Lexeo Therapeutics	-$0.87	-$0.78	+$0.09	-$0.78	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BDTX Black Diamond Therapeutics	N/A	N/A	N/A	N/A	N/A
LXEO Lexeo Therapeutics	N/A	N/A	N/A	N/A	N/A
PVCT Provectus Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A
RAPT Rapt Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BDTX Black Diamond Therapeutics	N/A	9.24	9.24
LXEO Lexeo Therapeutics	0.01	3.42	3.42
PVCT Provectus Biopharmaceuticals	N/A	0.11	0.11
RAPT Rapt Therapeutics	N/A	21.11	21.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BDTX Black Diamond Therapeutics	95.47%
LXEO Lexeo Therapeutics	60.67%
PVCT Provectus Biopharmaceuticals	0.05%
RAPT Rapt Therapeutics	99.09%

Insider Ownership

Company	Insider Ownership
BDTX Black Diamond Therapeutics	5.97%
LXEO Lexeo Therapeutics	5.30%
PVCT Provectus Biopharmaceuticals	14.70%
RAPT Rapt Therapeutics	2.36%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BDTX Black Diamond Therapeutics	90	56.86 million	53.47 million	Optionable
LXEO Lexeo Therapeutics	58	33.20 million	31.44 million	Not Optionable
PVCT Provectus Biopharmaceuticals	4	420.28 million	358.50 million	Not Optionable
RAPT Rapt Therapeutics	80	16.54 million	16.15 million	Optionable

PVCT, BDTX, LXEO, and RAPT Headlines

Recent News About These Companies

Rapt Therapeutics (NASDAQ:RAPT) Shares Gap Down - Time to Sell?

June 18 at 1:41 PM | marketbeat.com

Wall Street Analysts Predict a 282.65% Upside in Rapt Therapeutics (RAPT): Here's What You Should Know

June 18 at 10:55 AM | zacks.com

RAPT Finalizes Reverse Split Plan; 1-for-8 Ratio Effective June 16, 2025

June 15, 2025 | nasdaq.com

RAPT Therapeutics, Inc. Announces 1-for-8 Reverse Stock Split Effective June 16, 2025

June 15, 2025 | nasdaq.com

RAPT Therapeutics (NASDAQ:RAPT) Shares Scheduled to Reverse Split on Tuesday, June 17th

June 13, 2025 | marketbeat.com

RAPT Therapeutics, Inc.: RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split

June 13, 2025 | finanznachrichten.de

RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split

June 13, 2025 | globenewswire.com

Two Sigma Investments LP Sells 339,957 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT)

June 12, 2025 | marketbeat.com

Clear Street initiates Rapt Therapeutics stock with buy rating

June 7, 2025 | uk.investing.com

Rapt Therapeutics Get A Bullish Recommendation On ‘Significant Opportunity’ For Allergy Drug Candidate: Retail Worries About Cash Position

June 6, 2025 | msn.com

Rapt Therapeutics cuts staff for 2nd time in under a year, continuing fallout from FDA hold

June 4, 2025 | fiercebiotech.com

RAPT Therapeutics to Participate in Upcoming Investor Conferences

June 4, 2025 | globenewswire.com

RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Consensus Recommendation of "Hold" from Brokerages

June 3, 2025 | marketbeat.com

Short Interest in RAPT Therapeutics, Inc. (NASDAQ:RAPT) Rises By 39.9%

June 2, 2025 | marketbeat.com

What is HC Wainwright's Forecast for RAPT Q2 Earnings?

May 27, 2025 | marketbeat.com

12 Health Care Stocks Moving In Friday's Intraday Session

May 25, 2025 | benzinga.com

RAPT Therapeutics (NASDAQ:RAPT) Upgraded to "Hold" at Wall Street Zen

May 24, 2025 | marketbeat.com

UBS Group Issues Pessimistic Forecast for RAPT Therapeutics (NASDAQ:RAPT) Stock Price

May 24, 2025 | marketbeat.com

RAPT Therapeutics (NASDAQ:RAPT) Earns Buy Rating from HC Wainwright

May 24, 2025 | marketbeat.com

Rapt Therapeutics (RAPT) Upgraded to Buy: Here's What You Should Know

May 16, 2025 | zacks.com

RAPT Therapeutics Reports First Quarter 2025 Financial Results

May 8, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PVCT, BDTX, LXEO, and RAPT Company Descriptions

Black Diamond Therapeutics NASDAQ:BDTX

$2.33 0.00 (0.00%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$2.31 -0.02 (-1.07%)

As of 06/20/2025 07:39 PM Eastern

Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Lexeo Therapeutics NASDAQ:LXEO

$3.91 -0.33 (-7.78%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$3.89 -0.02 (-0.51%)

As of 06/20/2025 06:43 PM Eastern

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

Provectus Biopharmaceuticals OTCMKTS:PVCT

$0.07 0.00 (0.00%)

As of 06/20/2025 03:59 PM Eastern

Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis. It is also developing oral formulations for adult solid tumor cancers, as well as refractory and relapsed pediatric, and other blood cancers comprising leukemias; PV-10 for the treatment of relapsed and refractory pediatric solid tumor cancers; and other formulations for the treatment of cutaneous canine cancers and healing of full-thickness cutaneous wounds. In addition, the company develops oral and intranasal formulations for the treatment of severe acute respiratory syndrome coronavirus 2; gram-positive and gram-negative bacterial infections; oral bacterial infections; and fungal infections, as well as vertebrate development, wound healing, and tissue regrowth. It has collaboration agreement with Bascom Palmer Eye Institute; and University of Miami. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.

Rapt Therapeutics NASDAQ:RAPT

$7.43 +0.01 (+0.13%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$7.64 +0.22 (+2.89%)

As of 06/20/2025 04:20 PM Eastern

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time